PBIO
2024-03-31 | ||||
|---|---|---|---|---|
| Revenue generated | 349,257 | |||
| Selling and marketing | 130,173 | |||
| Research and development | 272,023 | |||
| General and administrative | 1,198,309 | |||
| Cost of goods sold | 233,310 | |||
| Expenses | 1,833,815 | |||
| (net loss) from operations | -1,484,558 | |||
| Other income (expense) | 2,482 | |||
| Interest expense, other | 5,384,991 | |||
| Gain (loss) on extinguishment of debt | -1,211,511 | |||
| Unrealized gain on investment in equity securities | 4,155 | |||
| Non-operating income (expenses) | -6,589,865 | |||
| Net (loss) | -8,074,423 | |||
| Preferred dividends | 632,053 | |||
| Net loss attributable to common stockholders | -8,706,476 | |||
| Basic eps | -0.22 | |||
| Diluted eps | -0.22 | |||
| Basic average shares | 39,811,524 | |||
| Diluted average shares | 39,811,524 | |||